The following manuscripts identify the NETest is more accurate (sensitive) than any other biomarker for the diagnosis of NET disease. These include initial and independent validation that the NETest is a bona fide NET diagnostic.
The following manuscripts demonstrate that elevated NETest scores are associated with poor progression free survival and can be used to identify those in whom disease will progress. Low scores, in contrast, are concordant with disease stability.
The following manuscripts demonstrate the clinical utility of the NETest in patients treated with somatostatin analogs or radionuclide therapy.
These manuscripts identify the clinical utility of the NETest in predicting response to radionuclide therapy.